![](https://library.celltelligence.com/wp-content/uploads/2022/09/Screenshot-2022-09-12-at-21.54.22.png)
$0
Clinical Updates from ADP-A2M4CD8’s SURPASS Study; Adaptimmune to Evaluate Multiple Combinations in the SURPASS Program; Adaptimmune’s ESMO 2022 Investor Event
On Friday, September 9, Adaptimmune held their ESMO 2022 Investor Event (press release / presentation) highlighting the clinical results from ADP-A2M4CD8’s (next-gen MAGE-A4 SPEAR-T) Ph1 SURPASS trial presented at ESMO 2022. Moreover, management disclosed future plans for the SURPASS family of trials. Below, Celltelligence provides insights on ADP-A2M4CD8’s updated clinical results, while discussing Adaptimmune’s new strategy to combine ADP-A2M4CD8 with checkpoint inhibitors.